FDA Drug Approval:

Review Time Has Decreased in Recent Years

PEMD-96-1: Published: Oct 20, 1995. Publicly Released: Nov 7, 1995.

Additional Materials:


Office of Public Affairs
(202) 512-4800

Pursuant to a congressional request, GAO provided data on the Food and Drug Administration's (FDA) new drug application (NDA) process, focusing on: (1) whether the timeliness of the review and approval process for new drugs changed in recent years; (2) the factors that distinguish NDA that are approved quickly from those that take longer to approve; (3) what distinguishes NDA that are approved from those that are not; and (4) how FDA drug approval process compares with the approval process in the United Kingdom.

GAO found that: (1) the average number of months for NDA to be approved by FDA decreased from 33 months in 1987 to 19 months in 1992; (2) the overall decrease in approval times was achieved through gradual reductions in the submission of all NDA from 1987 to 1992; (3) the priority FDA assigns to an NDA and the experience of its sponsor determine the timeliness and likelihood of the approval process; and (4) although comparable data is limited, the review times for FDA and its counterpart agency in the United Kingdom are similar.

Nov 13, 2018

Oct 30, 2018

Oct 23, 2018

Oct 15, 2018

Oct 1, 2018

Sep 28, 2018

Sep 17, 2018

Sep 13, 2018

Sep 10, 2018

Sep 6, 2018

Looking for more? Browse all our products here